All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Catch up with our live twitter coverage from the Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 2022.
Safety and efficacy of axatilimab in patients with cGvHD who have failed ≥2 lines of systemic therapy
Axatilimab (also known as SNDX‑6352), an immunoglobulin G4 monoclonal antibody, blocks colony stimulating factor-1 receptor-expressing monocytes and...
What is the latest update on biomarkers for assessing GvHD?
During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Carrie L. Kitko, Vanderbilt University Medical Center,...
Subscribe to get the best content related to GvHD delivered to your inbox